Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4461 Systemic anti-cancer therapy in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC): Insights from National Cancer Registration and Analysis Service (NCRAS)

Introduction: ENETS advocates the use of platinum-based chemotherapy in combination with Etoposide as first-line chemotherapy in advanced GEP-NEC. Available retrospective evidence is from small studies.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Paisey S, White B, Chandrakumaran K,

Keywords: Systemic anti-cancer therapy, Chemotherapy, GEP-NEC, NCRAS,

#4420 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced EP-NECs. Paclitaxel is also active in NECs however there is no data on the role of nab-paclitaxel.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Li S, Li J, Shen L, Lu M,

Keywords: extrapulmonary neuroendocrine carcinoma, nab-paclitaxel, bevacizumab,

#4244 Cell-free DNA (cfDNA) methylation profiling for minimally invasive cancer detection in patients with Extra-Pulmonary NeuroEndocrine Carcinoma (EP-NEC)

Introduction: Robust biomarkers to aid clinical management of patients (pts) with EP-NEC are lacking. cfDNA methylation profiling has shown higher sensitivity/specificity than cfDNA genome profiling in diagnosing and classifying various cancers, including Small Cell Lung Cancer (SCLC).

Conference:

Presenting Author: Frizziero M

Authors: Frizziero M, Pearce S, Clipson A, Rothwe D, Mouliere F,

Keywords: Extra-Pulmonary NeuroEndocrine Carcinoma, cfDNA, methylation profililing, biomarker,

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#4046 A single institution experience of clinic-molecular characterisation and correlation with treatment outcomes in patients with advanced extrapulmonary high grade neuroendocrine carcinomas: The NIRVANA study

Introduction: The gene mutation profiles of extra-pulmonary (EP) neuroendocrine carcinomas (NECs) and mixed neuroendocrine / non-neuroendocrine carcinomas (MiNENs) are incompletely understood.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: NEC, MiNEN, NGS, KRAS, TP53, MSI, extra-pulmonary,